Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 10/20 | 0.36 |
| ▸ | AKT2 | P31751 | 8/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729293 | 0.91 | AKT1 (0.45) | AKT1AKT3AKT2KITJAK1 | |
| SCHEMBL27821426 | 0.89 | AKT1 (0.43) | AKT1MAPK1AKT3AKT2KIT | |
| SCHEMBL3725412 | 0.89 | AKT1 (0.42) | AKT1MAPK1AKT3AKT2KIT | |
| SCHEMBL3725411 | 0.89 | AKT1 (0.42) | AKT1MAPK1AKT3AKT2KIT | |
| SCHEMBL3719679 | 0.85 | AKT1 (0.49) | AKT1AKT3AKT2KIT | |
| SCHEMBL3719675 | 0.85 | AKT1 (0.49) | AKT1AKT3AKT2KIT | |
| SCHEMBL3723838 | 0.85 | AKT1 (0.43) | AKT1MAPK1AKT3AKT2KIT | |
| SCHEMBL3723841 | 0.85 | AKT1 (0.43) | AKT1MAPK1AKT3AKT2KIT | |
| SCHEMBL3726798 | 0.84 | AKT1 (0.48) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL3726802 | 0.84 | AKT1 (0.48) | AKT1AKT3AKT2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | AKT1 537/4885MAPK1 229/4885AKT3 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.